143 related articles for article (PubMed ID: 25211092)
21. Treatment of localized oral MALT lymphoma by rituximab: a case report.
Yamagata K; Onizawa K; Kojima H; Yoshida H
Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
[TBL] [Abstract][Full Text] [Related]
22. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
23. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
24. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
[No Abstract] [Full Text] [Related]
25. [Mucosa-associated lymphoid tissue (MALT) lymphoma of the lung treated by surgery and rituximab; report of a case].
Yoshida C; Tarumi S; Kato A; Nii K; Chang SS; Yokomise H
Kyobu Geka; 2013 Feb; 66(2):169-72. PubMed ID: 23381369
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and therapeutic challenges.
Cantrill HL; Pulido JS; Donaldson M; Shields CL; Murray TG
Retina; 2008; 28(7):1018-22. PubMed ID: 18698308
[No Abstract] [Full Text] [Related]
27. Syndrome of inappropriate antidiuretic hormone secretion due to marginal zone lymphoma: responding to rituximab.
Bockorny B; Dasanu CA
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):220-2. PubMed ID: 22578816
[No Abstract] [Full Text] [Related]
28. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
Kang HJ; Kim WS; Kim SJ; Lee JJ; Yang DH; Kim JS; Lee SR; Lee GW; Kim HJ; Kim HY; Oh SY; Kim HC; Eom HS; Chung J; Park J; Suh C; Ryoo BY
Ann Hematol; 2012 Apr; 91(4):543-51. PubMed ID: 21922208
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland.
Heinz C; Merz H; Nieschalk M; Mueller-Miny H; Koch P; Heiligenhaus A
Br J Ophthalmol; 2007 Nov; 91(11):1563-4. PubMed ID: 17947275
[No Abstract] [Full Text] [Related]
30. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b.
Lachapelle KR; Rathee R; Kratky V; Dexter DF
Arch Ophthalmol; 2000 Feb; 118(2):284-5. PubMed ID: 10676800
[No Abstract] [Full Text] [Related]
31. Remission of acquired von Willebrand syndrome after successful treatment of gastric MALT lymphoma.
Biondo F; Matturro A; Santoro C; Leporace A; D'Elia G; Baldacci E; Pignoloni P; Pulsoni A; Foà R; Mazzucconi M
Haemophilia; 2012 Jan; 18(1):e34-5. PubMed ID: 22059776
[No Abstract] [Full Text] [Related]
32. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
33. A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.
Yazicioglu T; Oklar M; Kocabas S; Karadag E; Elibol V; Tezcan ME
Ocul Immunol Inflamm; 2022 Aug; 30(6):1329-1333. PubMed ID: 36084297
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TF; Muche R; Dreyhaupt J; Buske C
Future Oncol; 2020 May; 16(13):817-825. PubMed ID: 32223334
[TBL] [Abstract][Full Text] [Related]
35. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
36. Possible clinical effects of macrolides on the treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma.
Yatera K; Ishimatsu Y; Sakamoto N; Mukae H
Int J Hematol; 2016 Feb; 103(2):251-2. PubMed ID: 26590918
[No Abstract] [Full Text] [Related]
37. An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature.
Gentile G; Broccoli A; Brunocilla E; Schiavina R; Borghesi M; Romagnoli D; Bianchi L; Derenzini E; Agostinelli C; Franceschelli A; Colombo F; Zinzani PL
Anticancer Res; 2013 Jun; 33(6):2639-42. PubMed ID: 23749921
[TBL] [Abstract][Full Text] [Related]
38. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
39. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
40. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
